Glucose, High Blood Clinical Trial
— LEVPSOfficial title:
A Randomised, Multiple-Dose, Single Period, Phase II/III Dose Response Study to Examine Transdermal Human Insulin in Adult Diabetic Patients
A 21-Day open label study of transdermally delivered human insulin in Type 2 Diabetics as measured by response of down modulation of glucose after dosing of Insulin as compared to historic patient response to injected insulins.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | February 15, 2025 |
Est. primary completion date | December 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Adult Type 2 Diabetes Mellitus ("T2D") Patients on Insulin Replacement therapy not administered via implanted pump well-managing p.r.n as defined by serum glucose ranging between 85 and 200 mg/dL and no more than 1 hypoglycemic or serious hypoglycemic event within the last 9 months. 2. 25 and 75 years of age, inclusive. 3. The subject is willing and able to read and understand the Subject Information Sheet and provide written informed consent. 4. The subject has a body mass index (BMI) within 18-50 kg/m2. 5. The subject is in otherwise good health as determined by medical history and physical examination. 6. The subject's normal insulin dose ranges from between 10 to 200 IU per dose. 7. The subject must agree to continue with daily serum glucose testing by means of a wearable blood glucose monitor for the pharmacodynamic assessments that the investigators have continuous access to via daily downloads. 8. The subject is willing and able to comply with all testing and requirements defined in the protocol. 9. The subject is willing and able to return to the study site for all visits. Exclusion Criteria: 1. The subject has any relevant deviations from normal other than blood glucose in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator. 2. The subject has had more than 2 hypoglycemic events in the last month. 3. The subject's normal insulin dose is less than 10 and more than 200 IUs. 4. Subjects receiving Insulin from an implanted or external insulin pump system. 5. The subject has had a clinically significant illness or surgical procedure within 30 days preceding entry into this study. 6. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease other than T2D. 7. The subject has a known allergy or history of hypersensitivity to Human Insulin or similar modified Insulin compounds. 8. The subject has used any prescription medication that may interfere with the evaluation of study medication. 9. The subject has donated or lost a significant volume of blood (>450 mL) within four (4) weeks of the study, and subject's Hemoglobin concentration and hematocrit have not returned to within 5% of normal. 10. The subject has a history of substance abuse or a current positive urine drug screen or urine alcohol test. 11. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males). 12. Subjects who have received an investigational drug or have used an investigational device in the 30 days prior to study entry. |
Country | Name | City | State |
---|---|---|---|
United States | Langford Research Institute | Palm Beach Gardens | Florida |
Lead Sponsor | Collaborator |
---|---|
Transdermal Delivery Solutions Corp | Langford Research Institute, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Glucose Time in Range for Study Participants | Number of Participants who manage blood glucose in study participants to between 70 and 200 mg Glucose / dL. | 21 Days | |
Secondary | Avoidance of Hypoglycemia in Study Participants | Number of study participants that manage blood glucose in study participants to more than 50 mg/dL for 86% of the 21-days-on-dose of the study period | 21 days. | |
Secondary | Skin Safety in Study Participants | Measure of skin irritation above level 1 - erythema & edema - according to the The Organisation for Economic Co-operation and Development (OECD) Guideline for Testing of Chemicals No. 404, adopted 17th July, 1992: "Acute Dermal Irritation/Corrosion" | 21 days dosing plus 7 days post dose follow-up. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04230694 -
Continuous Glucose Monitoring of Hospitalized Patients With Diabetes
|
N/A | |
Active, not recruiting |
NCT04641689 -
Stand Up Kansas: An Intervention to Reduce Sedentary Behavior in the Home Work Environment
|
N/A | |
Active, not recruiting |
NCT05056376 -
Effectiveness and Cost-Effectiveness of Fully-Automated Digital vs. Human Coach-Based Diabetes Prevention Programs
|
N/A | |
Completed |
NCT04547023 -
Fasting Versus Fed: Effect of Oral Intake Prior to the Glucose Tolerance Test in Pregnancy
|
N/A | |
Completed |
NCT04648397 -
The Effect of Chewing Duration on Blood Glucose Levels
|
N/A | |
Enrolling by invitation |
NCT04846751 -
Exercise Type That Faster Reduces Postprandial Glycemia.
|
N/A | |
Active, not recruiting |
NCT04893148 -
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
|
Phase 4 | |
Active, not recruiting |
NCT01028846 -
Central Mechanisms That Regulate Glucose Metabolism in Humans
|
Phase 4 | |
Completed |
NCT03252704 -
Post-prandial Glycemic Response to Fiber in Healthy Adults
|
N/A | |
Completed |
NCT05215210 -
The Effect of Long-term Momordica Charantia Supplementation on Blood Glucose Levels
|
N/A | |
Completed |
NCT03972878 -
Foodprint 1.0: Physiological Acute Responses After Consumption of Confectionary Products
|
N/A | |
Completed |
NCT05071950 -
The Effect of D-allulose on the Glycemic Changes in Patients With Type 2 Diabetes Mellitus During Ramadan Fasting
|
N/A | |
Suspended |
NCT03428295 -
Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC
|
Phase 1/Phase 2 | |
Suspended |
NCT03566511 -
Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide
|
Phase 2 | |
Completed |
NCT04483453 -
Effect of Nutritional Intervention on Metabolic Response in Infants
|
N/A | |
Completed |
NCT03344185 -
The Effect of Glycaemic Index Variation on Blood Glucose and Mood in Healthy Participants Across the Day
|
N/A | |
Completed |
NCT03544411 -
Effects of Olive Oil and Bran Oil on Antioxidant Levels, Glycemic Control, and Lipid Profile in Patient Type 2 DM
|
Phase 1 | |
Completed |
NCT05182190 -
Effects of Black Bean Pasta Consumption on Biomarkers in Young Adults
|
N/A | |
Completed |
NCT04438018 -
Towards a Better Understanding of Diabetes Distress, Depression and Poor Glycaemic Control in T2DM
|
||
Completed |
NCT03811132 -
Towards a Better Understanding of Diabetes Distress, Depression and Poor Glycaemic Control (DIA-LINK Study)
|